Sebastiano Mercadante1, Francesco Masedu2, Isabella Balzani3, Daniela De Giovanni4, Luigi Montanari5, Cristina Pittureri6, Raffaella Bertè7, Domenico Russo8, Laura Ursini9, Franco Marinangeli10, Federica Aielli11. 1. Palliative care program SAMO and University of Palermo, Palermo, Italy. terapiadeldolore@lamaddalenanet.it. 2. Department of Biotechnological and Applied Clinical Sciences, Section of Clinical Epidemiology and Environmental Medicine, University of L'Aquila, L'Aquila, Italy. 3. Palliative Care Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Forlì-Cesena, Italy. 4. Palliative Care Unit, Casale Monferrato, Alessandria, Italy. 5. Palliative Care Unit, AUSL Della Romagna, Ravenna, Italy. 6. Palliative Care and Hospice Unit, AUSL Romagna, Cesena, Italy. 7. Palliative Care, Oncology Department, Guglielmo da Saliceto Hospital, Piacenza, Italy. 8. "San Marco" Hospice and Palliative Care, Latina, Italy. 9. "Casa Margherita" Hospice, ASL 01 Avezzano-Sulmona-L'Aquila, L'Aquila, Italy. 10. Anesthesiology and Pain Medicine, Department of Life Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy. 11. Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
Abstract
AIM: The aim of this study was to assess the prevalence of delirium in advanced cancer patients admitted to different palliative care services in Italy and possible related factors. The secondary outcome was to assess the changes of delirium after 1 week of palliative care. METHODS: A consecutive sample of patients was screened for delirium in period of 1 year in seven palliative care services. General data, including primary tumor, age, gender, concomitant disease, palliative prognostic score (PaP), and Karnofsky status, were collected. Possible causes or factors associated with delirium were looked for. The Edmonton Symptom Assessment Scale was used to assess physical and psychological symptoms and the Memorial Delirium Assessment Scale (MDAS) to assess the cognitive status of patients, at admission (T0) and 1 week after palliative care (T7). RESULTS: Of 848 patients screened, 263 patients were evaluated. Sixty-six patients had only the initial evaluation. The mean Karnofsky status was 34.1 (SD = 6.69); the mean PaP score at admission was 6.9 (SD = 3.97). The mean duration of palliative care assistance, equivalent to survival, was 38.4 days (SD = 48, range 2-220). The mean MDAS values at admission and after 1 week of palliative care were 6.9 (SD = 6.71) and 8.8 (SD = 8.26), respectively. One hundred ten patients (41.8%) and 167 patients (67.3%) had MDAS values ≥ 7 at admission and after 1 week of palliative care, respectively. Age, dehydration, cachexia, chemotherapy in the last three months, and intensity of drowsiness and dyspnea were independently associated with a MDAS > 7. A worsening of drowsiness, the use of opioids, and the use of corticosteroids were independently associated with changes of MDAS from T0 to T7. CONCLUSION: Although the prevalence of delirium seems to be similar to that reported in other acute settings, delirium tended to worsen or poorly responded to a palliative care treatment. Some clinical factors were independently associated with delirium. This information is relevant for decision-making when delirium does not change despite a traditional intervention. Continuous assessment of delirium should be performed in these settings to detect deterioration of cognitive function. Further studies should elucidate whether an earlier approach to palliative care would decrease the prevalence of delirium at a late stage of disease.
AIM: The aim of this study was to assess the prevalence of delirium in advanced cancerpatients admitted to different palliative care services in Italy and possible related factors. The secondary outcome was to assess the changes of delirium after 1 week of palliative care. METHODS: A consecutive sample of patients was screened for delirium in period of 1 year in seven palliative care services. General data, including primary tumor, age, gender, concomitant disease, palliative prognostic score (PaP), and Karnofsky status, were collected. Possible causes or factors associated with delirium were looked for. The Edmonton Symptom Assessment Scale was used to assess physical and psychological symptoms and the Memorial Delirium Assessment Scale (MDAS) to assess the cognitive status of patients, at admission (T0) and 1 week after palliative care (T7). RESULTS: Of 848 patients screened, 263 patients were evaluated. Sixty-six patients had only the initial evaluation. The mean Karnofsky status was 34.1 (SD = 6.69); the mean PaP score at admission was 6.9 (SD = 3.97). The mean duration of palliative care assistance, equivalent to survival, was 38.4 days (SD = 48, range 2-220). The mean MDAS values at admission and after 1 week of palliative care were 6.9 (SD = 6.71) and 8.8 (SD = 8.26), respectively. One hundred ten patients (41.8%) and 167 patients (67.3%) had MDAS values ≥ 7 at admission and after 1 week of palliative care, respectively. Age, dehydration, cachexia, chemotherapy in the last three months, and intensity of drowsiness and dyspnea were independently associated with a MDAS > 7. A worsening of drowsiness, the use of opioids, and the use of corticosteroids were independently associated with changes of MDAS from T0 to T7. CONCLUSION: Although the prevalence of delirium seems to be similar to that reported in other acute settings, delirium tended to worsen or poorly responded to a palliative care treatment. Some clinical factors were independently associated with delirium. This information is relevant for decision-making when delirium does not change despite a traditional intervention. Continuous assessment of delirium should be performed in these settings to detect deterioration of cognitive function. Further studies should elucidate whether an earlier approach to palliative care would decrease the prevalence of delirium at a late stage of disease.
Entities:
Keywords:
Advanced cancer; Delirium; Home care; Hospice care; Palliative care
Authors: A Caraceni; O Nanni; M Maltoni; L Piva; M Indelli; E Arnoldi; M Monti; L Montanari; D Amadori; F De Conno Journal: Cancer Date: 2000-09-01 Impact factor: 6.860
Authors: L Grassi; A Caraceni; E Beltrami; C Borreani; M Zamorani; M Maltoni; M Monti; M Luzzani; S Mercadante; F De Conno Journal: J Pain Symptom Manage Date: 2001-01 Impact factor: 3.612
Authors: David Hui; Renata dos Santos; Suresh Reddy; Maria Salete de Angelis Nascimento; Donna S Zhukovsky; Carlos Eduardo Paiva; Shalini Dalal; Everaldo Donizeti Costa; Paul Walker; Heloisa Helena Scapulatempo; Rony Dev; Camila Souza Crovador; Maxine De La Cruz; Eduardo Bruera Journal: Palliat Med Date: 2015-04-16 Impact factor: 4.762
Authors: Seong Hoon Shin; David Hui; Gary B Chisholm; Jung Hye Kwon; Maria Teresa San-Miguel; Julio A Allo; Sriram Yennurajalingam; Susan E Frisbee-Hume; Eduardo Bruera Journal: J Pain Symptom Manage Date: 2013-11-15 Impact factor: 3.612
Authors: Elizabeth A Luth; Paul K Maciejewski; Veerawat Phongtankuel; Jiehui Xu; Holly G Prigerson Journal: J Pain Symptom Manage Date: 2020-10-07 Impact factor: 3.612
Authors: Christine L Watt; Franco Momoli; Mohammed T Ansari; Lindsey Sikora; Shirley H Bush; Annmarie Hosie; Monisha Kabir; Erin Rosenberg; Salmaan Kanji; Peter G Lawlor Journal: Palliat Med Date: 2019-06-11 Impact factor: 4.762